Overview

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

Status:
Recruiting

Trial end date:
2021-08-05

Target enrollment:

Participant gender:

Summary

There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab